- Bacterial Toxin Implicated In Young Adult Colon Cancers
- Exposure Therapy For Peanut Allergy Effective In Adults
- Program Matches Breast Cancer Patients To Exercise, Rehab
- AI Predicts Wasting Syndrome In Cancer Patients
- Ready-Made Immune Therapy Effective Against Leukemia
- Ultra-Processed Foods Increase Risk Of Early Death
- Head Injuries Are a Growing Risk for Anesthesiologists, Experts Warn
- Where Have All The Insects Gone — And Why?
- HHS Announces Plans to Pay Moderna $176 Million for mRNA Flu Vaccine
- Novavax COVID Vaccine Moves Closer to Full FDA Approval
Health Highlights: May 2, 2016

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Huge Price Increases for Oral Cancer Drugs Since 2000: Study
Prices of oral cancer drugs in the United States have risen sharply since 2000, a new study finds.
The average cost of a new oral cancer drug introduced in 2000 was about $1,869 a month, compared with $11,325 a month for one approved in 2014, about six times higher, United Press International reported.
Gleevec had one of the largest price increases during that time, rising about 7.5 percent a year and increasing from $3,346 to $8,479 a month, according to the University of North Carolina researchers.
The study was published in the journal JAMA Oncology.
The researchers said the skyrocketing prices have occurred along with health insurance changes making patients bear more of the cost, and potentially making treatment unaffordable for some, UPI reported.
Copyright © 2025 HealthDay. All rights reserved.